E7090

1 clinical trial

1 abstract

2 indications

Indication

Abstract

Phase Ib trial of tasurgratinib (E7090) with or without endocrine therapies for patients (pts) with ER+, HER2− recurrent/metastatic breast cancer (BC) after receiving a CDK4/6 inhibitor.

Org: Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan, Tohoku University Hospital, Miyagi, Japan, National Center for Global Health and Medicine, Tokyo, Japan, NHO Shikoku Cancer Center, Ehime, Japan, Showa University, Tokyo, Japan,

Clinical trial

Multicenter Investigator-initiated Phase II Trial of E7090 in Patients With Advanced or Recurrent Solid Tumor With Fibroblast Growth Factor Receptor (FGFR) Gene Alteration (FORTUNE Trial)

Status: Active (not recruiting), Estimated PCD: 2024-12-31